CompletedNot Applicable

Efficacy and Safety on the Use of Bisphosphonates in Paediatrics

France99 participantsStarted 2018-10-31

Plain-language summary

The investigators suppose that the impact of bisphosphonate therapy is beneficial on the bone during the growth period with few adverse events.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * be under 18 years of age * have been treated by intravenous bisphosphonates for primary or secondary osteoporosis Exclusion Criteria: * be over 18 years of age

What they're measuring

fracture rates

Timeframe: 2 years

bone mineral density

Timeframe: 2 years

pain frequency

Timeframe: 2 years

Trial details

NCT IDNCT04012320

SponsorCentre Hospitalier Universitaire de Nīmes

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-12-31

View on ClinicalTrials.gov More Bone Fragile trials